Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01280
|
|||||
| Drug Name |
Enoxacin
|
|||||
| Synonyms |
1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid; AT 2266; AT-2266; AT2266; Almitil; Almitil (TN); Bactidan; Bactidan (TN); Bactidron (TN); CI919; CL23362; Comprecin; Comprecin (TN); E0762; Enoksetin (TN); Enoram; Enoxacin (USAN/INN); Enoxacin Sesquihydrate; Enoxacin [USAN:BAN:INN:JAN]; Enoxacine; Enoxacine [French]; Enoxacino; Enoxacino [Spanish]; Enoxacinum; Enoxacinum [Latin]; Enoxen (TN); Enoxin; Enoxin (TN); Enoxor; Enoxor (TN); Enroxil (TN); Faulding Brand of Enoxacin; Flumark; Flumark (TN); Gyramid (TN); PD 107779; PD-107779; PD107779; Penetrex; Penetrex (TN); Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Urinary tract infections [ICD11:GC08] | Approved | [1] | |||
| Gonorrhea [ICD11:1A70-1A7Z] | Approved | [1] | ||||
| Therapeutic Class |
Antiinfective Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H17FN4O3
|
|||||
| Canonical SMILES |
CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
|
|||||
| InChI |
InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
|
|||||
| InChIKey |
IDYZIJYBMGIQMJ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 74011-58-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 320.32 | Topological Polar Surface Area | 85.8 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-0.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9193
,494643
,598045
,855964
,7656850
,7847376
,7979166
,8149934
,8152051
,10321663
,11112842
,11335595
,11360834
,11364433
,11366995
,11369557
,11372679
,11373790
,11377719
,11414007
,11461806
,11466381
,11467501
,11485538
,11486102
,11489547
,11491385
,11491981
,11495353
,12012631
,14899277
,24894528
,26612426
,26680210
,26747059
,26747060
,29222370
,46507505
,47216718
,47365122
,47365123
,47440190
,47736413
,47885347
,48110393
,48110394
,48184940
,48334424
,48415943
,49698449
|
|||||
| ChEBI ID |
CHEBI:157175
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| References | ||||||
| 1 | Enoxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34. | |||||
| 3 | Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.